Cigna Corporation (CI) — Fair Value Analysis

Base-case fair value (P50): $390.41 · Current price: $285.27 · Verdict: Undervalued

The Verdict on CI

Based on rigorous Monte Carlo simulations, Cigna (CI) is currently deemed Deeply Undervalued. The company's median fair value (P50) is projected at $390.41, standing in stark contrast to its present trading price of $285.27. This analysis suggests a substantial +36.9% potential from current levels, pointing to a significant valuation gap that investors may find compelling. The simulations indicate that the market is not fully appreciating the intrinsic value of this Healthcare sector stalwart.

How CI stacks up against Healthcare

Despite being categorized with an "average" quality tier for its operational and financial health relative to the broader Healthcare sector, CI's valuation disconnect remains pronounced. The Monte Carlo framework accounts for this average quality, yet still consistently identifies a robust upside. This suggests that even within a sector known for its complexity and varying performance metrics, CI's current market valuation of $285.27 offers a compelling entry point compared to its simulated fair value of $390.41. The quality tier does not negate the significant +36.9% uncovered by our models.

What this means for investors

For investors, the Monte Carlo simulation's "Deeply Undervalued" verdict for CI highlights a notable opportunity. The projected +36.9% suggests that Cigna's share price has considerable room to run towards its intrinsic value of $390.41 from its current $285.27. This robust probabilistic analysis, a cornerstone of the FairCurve platform, provides a forward-looking perspective on CI's potential. Unlock the full Monte Carlo distribution, including bear (P10) and bull (P90) scenarios, and track CI's fair value as new fundamentals are released by signing up for FairCurve.